==============================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
----------------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number 1-9601
Date of Report (date of earliest event reported): June 16, 2008
K-V PHARMACEUTICAL COMPANY
(Exact name of registrant as specified in its charter)
DELAWARE 43-0618919
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
2503 SOUTH HANLEY ROAD
ST. LOUIS, MISSOURI 63144
(Address of principal executive offices) (Zip Code)
(314) 645-6600
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of
the following provisions:
/ / Written communications pursuant to Rule 425 under the Securities Act.
/ / Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
/ / Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act.
/ / Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act.
==============================================================================
Item 2.02 Results of Operations and Financial Condition.
On June 16, 2008, K-V Pharmaceutical Company issued a press
release announcing its preliminary financial results for the
fourth quarter and fiscal year ended March 31, 2008. A copy
of that press release is furnished as an exhibit to this
report and is incorporated herein by reference.
The information in this report, including the exhibit, shall
not be deemed "filed" for purposes of Section 18 of the
Securities Exchange Act of 1934 or otherwise subject to the
liabilities of that section. K-V Pharmaceutical Company has
posted this Form 8-K on its internet website at
www.kvpharmaceutical.com.
Item 9.01 Financial Statements and Exhibits.
(d) The following exhibit is furnished as part of this report:
Exhibit Number Description
-------------- -----------
99 Press Release dated June 16, 2008, issued
by K-V Pharmaceutical Company
* * *
-2-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Dated: June 16, 2008
K-V PHARMACEUTICAL COMPANY
By: /s/ Richard H. Chibnall
------------------------------------
Richard H. Chibnall
Vice President, Finance